Trial Profile
Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer: a Multicenter, Single-arm, Explorative Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results (As of January 31, 2023, n=21) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 20 Aug 2021 New trial record